Eyenovia (NSDQ:EYEN) said this week that the results of its Phase II PG21 study were published in the Nov. issue of the journal Clinical Ophthalmology.
The New York-based company’s Phase II study evaluated the effect of self-administered micro-dose latanoprost on intraocular pressure.
Get the full story at our sister site, Drug Delivery Business News.
The post Eyenovia touts publication of intraocular pressure data for micro-dose tech appeared first on MassDevice.